• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Three Health-Care Picks That Should Weather Reform

    Matrix Advisors Value manager David Katz explains the fund's new Zimmer, Genzyme, and Medtronic picks amid a still-uncertain health-care environment.

  2. Pfizer Shares Still Attractive

    A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.

  3. Even After Patent Cliff, Pfizer Is Undervalued

    A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.

  4. Can They Deliver?

    Morningstar markets editor Jeremy Glaser looks at if the congressional supercommittee, Coach, Pfizer, Comcast, and Kraft can deliver the goods.

  1. Pfizer Inc. PFE Q3 2010 Earnings Call Transcript

    Good day everyone, and welcome to Pfizer s Third Quarter 2010 Earnings Conference Call. Today s call is being recorded.

  2. Pfizer Inc. PFE Q1 2010 Earnings Call Transcript

    Good day everyone and welcome to Pfizer s First Quarter 2010 Earnings Conference Call. Today s call is being recorded.

  3. Pfizer Inc. PFE Q4 2010 Earnings Call Transcript

    Good day, everyone, and welcome to Pfizer s Fourth Quarter 2010 Earnings Conference Call. Today s call is being recorded.

  4. Emerging Nations: A Blossoming Field For Drug and Medical-Device Firms

     

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.